FTC Antitrust Enforcement in Healthcare: The New Enforcement Paradigm

Introduction

The Federal Trade Commission has historically treated healthcare as a priority enforcement sector, and recent years have intensified this focus. Healthcare deals face Second Request rates that significantly exceed the cross-industry average (which runs approximately 2-3% of all HSR filings). The elevated scrutiny reflects the FTC's view that healthcare market concentration directly impacts consumer welfare through higher prices, reduced access, and diminished quality of care. For healthcare bankers, understanding FTC enforcement patterns is essential because antitrust risk directly affects deal certainty, valuation (through reverse termination fees and conditionality), and the strategic calculus of potential acquirers.

Innovation Market Theory in Pharma

The FTC has pioneered the "innovation market" theory in pharmaceutical antitrust, challenging mergers not just based on overlap in existing commercial products but based on overlap in pipeline programs that may compete in the future.

Innovation Market Theory

An antitrust framework in which the FTC defines the relevant market based on R&D pipelines rather than commercial products. If two merging pharma companies both have drug candidates targeting the same disease with similar mechanisms of action, the FTC may argue that the merger would eliminate potential future competition, even though neither product is yet on the market. This theory has been used to require divestitures of pipeline assets as a condition of merger approval. The theory is controversial because it requires the FTC to predict which pipeline programs will succeed and how they would compete, introducing significant uncertainty into the merger review process.

The practical impact of innovation market theory is significant for biopharma M&A. Pharma companies contemplating acquisitions must analyze not only commercial product overlap (which they already do) but also pipeline overlap, including early-stage programs that may be years from market. Divestitures of pipeline assets are increasingly common conditions for FTC approval.

Serial Acquisition Scrutiny

The FTC has increasingly targeted the platform and add-on strategy that drives healthcare services PE activity. The concern is that individual add-on acquisitions may be too small to trigger HSR filing requirements (below the approximately $119.5 million threshold), but the cumulative effect of dozens of sub-threshold acquisitions creates market concentration that would have been challenged if achieved through a single large transaction.

PE-Focused Enforcement

The FTC has expanded its enforcement lens to treat PE firms as single economic entities across their portfolio companies. If a PE firm owns two healthcare services platforms in adjacent but overlapping markets, the FTC may analyze a new acquisition by either platform in the context of the combined PE firm's total market position.

Several recent enforcement actions illustrate the FTC's healthcare approach:

Edwards/JenaValve (2024): The FTC challenged Edwards Lifesciences' proposed acquisition of JenaValve Technology in the transcatheter aortic valve replacement (TAVR) market. The FTC argued the deal would eliminate a potential competitor in a market Edwards already dominated. The challenge demonstrated the FTC's willingness to use innovation market theory to block device transactions, not just pharma deals.

GTCR/Surmodics (2024): The FTC challenged the PE firm GTCR's proposed acquisition of Surmodics, a medical device coatings and in vitro diagnostics company. The FTC lost this challenge in court, an important outcome that demonstrated limits to the FTC's enforcement reach and provided precedent for future contested healthcare deals.

Aya Healthcare/Cross Country (2025): Aya Healthcare abandoned its proposed acquisition of Cross Country Healthcare (healthcare staffing) after the FTC expressed opposition, citing concerns about concentration in the travel nurse staffing market.

FTC enforcement risk directly shapes how healthcare deals are structured:

Reverse termination fees (RTFs) are negotiated into approximately 58% of healthcare deals, compensating the seller if the deal fails due to regulatory challenge. RTFs average 4.76% of deal value and represent the buyer's financial commitment to pursuing regulatory clearance. Higher RTF percentages signal greater buyer confidence in closing.

Extended outside dates of 12-18 months (versus 6-9 months in other sectors) account for the longer regulatory approval timeline and the possibility of FTC litigation.

Divestiture provisions are increasingly pre-negotiated, with buyer and seller agreeing in advance on which assets the buyer would divest to satisfy FTC concerns. These "fix-it-first" strategies can accelerate FTC review and reduce deal uncertainty.

The next article covers deal certainty mechanisms, including reverse termination fees, ticking fees, and outside dates that compensate parties for healthcare's uniquely long regulatory timelines.